Eur Rev Med Pharmacol Sci 2019; 23 (24): 10575-10576
DOI: 10.26355/eurrev_201912_19752

D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets

A.S. Laganà, V. Unfer

Department of Obstetrics and Gynecology, “Filippo Del Ponte” Hospital, University of Insubria, Varese, Italy. vunfer@gmail.com

Free PDF Download

To cite this article

A.S. Laganà, V. Unfer
D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 24
Pages: 10575-10576
DOI: 10.26355/eurrev_201912_19752

Keywords Related articles:

  1. The Combined therapy with myo-inositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
  2. Bye-bye Chiro-inositol – Myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction
  3. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial
  4. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients
  5. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios